Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Feb:242:108344.
doi: 10.1016/j.pharmthera.2023.108344. Epub 2023 Jan 9.

RET aberrant cancers and RET inhibitor therapies: Current state-of-the-art and future perspectives

Alfredo Addeo  1 , Ernesto Miranda-Morales  2 , Petra den Hollander  3 , Alex Friedlaender  1 , Herman O Sintim  4 , Jie Wu  5 , Sendurai A Mani  3 , Vivek Subbiah  6
Affiliations
Review

RET aberrant cancers and RET inhibitor therapies: Current state-of-the-art and future perspectives

Alfredo Addeo et al. Pharmacol Ther. 2023 Feb.

Abstract

Precision oncology informed by genomic information has evolved in leaps and bounds over the last decade. Although non-small cell lung cancer (NSCLC) has moved to center-stage as the poster child of precision oncology, multiple targetable genomic alterations have been identified in various cancer types. RET alterations occur in roughly 2% of all human cancers. The role of RET as oncogenic driver was initially identified in 1985 after the discovery that transfection with human lymphoma DNA transforms NIH-3T3 fibroblasts. Germline RET mutations are causative of multiple endocrine neoplasia type 2 syndrome, and RET fusions are found in 10-20% of papillary thyroid cases and are detected in most patients with advanced sporadic medullary thyroid cancer. RET fusions are oncogenic drivers in 2% of Non-small cell lung cancer. Rapid translation and regulatory approval of selective RET inhibitors, selpercatinib and pralsetinib, have opened up the field of RET precision oncology. This review provides an update on RET precision oncology from bench to bedside and back. We explore the impact of selective RET inhibitor in patients with advanced NSCLC, thyroid cancer, and other cancers in a tissue-agnostic fashion, resistance mechanisms, and future directions.

Keywords: Clinical trials; Non-small cell lung cancer; RET; RET fusions; Thyroid cancer; Tissue-agnostic.

PubMed Disclaimer

Conflict of interest statement

Declaration of Competing Interest V. Subbiah reports grants from Eli Lilly/LOXO Oncology, Blueprint Medicines Corporation, Turning Point Therapeutics, Boston Pharmaceuticals; and grants from Helsinn Pharmaceuticals during the conduct of the study; in addition, V. Subbiah reports a grant and advisory board/consultant position with Eli Lilly/Loxo Oncology during the conduct of the study; research grants from Roche/Genentech, Bayer, GlaxoSmithKline, Nanocarrier, Vegenics, Celgene, Northwest Biotherapeutics, Berghealth, Incyte, Fujifilm, D3, Pfizer, Multivir, Amgen, Abbvie, Alfa-sigma, Agensys, Boston Biomedical, Idera Pharma, Inhibrx, Exelixis, Blueprint Medicines, Altum, Dragonfly Therapeutics, Takeda, National Comprehensive Cancer Network, NCI-CTEP, University of Texas MD Anderson Cancer Center, Turning Point Therapeutics, Boston Pharmaceuticals, Novartis, Pharmamar, Medimmune; an advisory board/consultant position with Helsinn, Incyte, QED Pharma, Daiichi-Sankyo, Signant Health, Novartis, Relay therapeutics, Pfizer, Roche, Medimmune; travel funds from Pharmamar, Incyte, ASCO, ESMO; other support from Medscape; all outside the submitted work.

Figures

Fig. 1.
Fig. 1.
RET mechanisms in normal and oncogenic states. (1) Wild-type RET is a transmembrane protein with extracellular cadherin-like and cysteine-rich domains and an intracellular tyrosine kinase domain and isoform-specific tail. (2) Upon binding of the wild-type RET to a GFRα bound to a GDNF family ligand, RET homodimerizes, is autophosphorylated, and activates signaling through RAS, RAF, MEK, or ERK pathways. Ligands are color-coded (GDNF in red, NRTN in yellow, ARTN in green, and PSPN in blue), and respective GFRα receptors are color-matched. Calcium-binding is represented by bright green crosses and phosphorylation by the letter p in a yellow circle. (3) RET with oncogenic mutations, such as those indicated, is constitutively active. (4) Oncogenic RET with two of the most common fusions, CCDC6 and KIF58, is intracellular, undergoes ligand-independent dimerization, and is constitutively active.
Fig. 2.
Fig. 2.
RET inhibitor resistance mechanisms. The RET V804M/L gate-keeper mutations confer resistance to MKIs but are overcome by selective RET inhibitors. Solvent front mutations (e.g., RET G10S/C/R) confer resistance to selective RET inhibitors. Mutations or amplifications of MET or NTRK underlie off-target mechanisms of resistance to selective RET inhibitor therapy. EMT may also play a role in acquisition of RET inhibitor resistance.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Adashek JJ, Subbiah V, & Kurzrock R (2020). From tissue-agnostic to N-of-one therapies: (R)evolution of the precision paradigm. Trends Cancer. 7(1), P15–28 JANUARY 01, 2021. - PubMed
    1. Adashek JJ, Desai AP, Andreev-Drakhlin AY, Roszik J, Cote GJ, & Subbiah V (2021). Hallmarks of RET and co-occuring genomic alterations in RET-aberrant cancers. Molecular Cancer Therapeutics 20, 1769–1776. - PMC - PubMed
    1. Addeo A, Passaro A, Malapelle U, Luigi Banna G, Subbiah V, & Friedlaender A (2021). Immunotherapy in non-small cell lung cancer harbouring driver mutations. Cancer Treatment Reviews 96, Article 102179. - PubMed
    1. Airaksinen MS, Titievsky A, & Saarma M (1999). GDNF family neurotrophic factor signaling: Four masters, one servant? Molecular and Cellular Neurosciences 13, 313–325. - PubMed
    1. Anders J, Kjar S, & Ibanez CF (2001). Molecular modeling of the extracellular domain of the RET receptor tyrosine kinase reveals multiple cadherin-like domains and a calcium-binding site. The Journal of Biological Chemistry 276, 35808–35817. - PubMed

Publication types

MeSH terms

Substances